Modus Therapeutics publishes interim report for the first quarter 2022

Report this content

STOCKHOLM, SWEDEN - 16 May 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the first quarter 2022. The report is available as an attached document and on the company's website ( Below is a summary of the interim report.

The first quarter in figures

  • The loss after tax amounted to TSEK 3 065 (1 428).
  • The loss per share amounted to SEK 0,19 (0,17).
  • The cash flow from current operations was negative in the amount of TSEK 7 545 (1 166).

Important events during the quarter

  • Modus presented at Erik Penser Bank's Health Care day.

Important events after the end of the period

  • Modus participated in Swiss Nordic Bio.
  • Modus participated in BIO-Europe 2022.
  • Modus presented at LSX world congress.
  • The annual general meeting was held on 11 May 2022
  • Modus Therapeutics secures access to bridge financing from Karolinska Development

The interim report will also be presented at an investor webcast today May 16th, 2022, at 13:00CET. The webcast can be accessed via the following link: or via the Modus website.

This information is such information that Modus Therapeutics Holding AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person below, for publication on May 16th, 2022.

For more information on Modus Therapeutics, please contact:

John Öhd, VD, Modus Therapeutics

Phone: +46 (0) 70 766 80 97


Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Phone: +46 11 32 30 732


About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Documents & Links